Gilead obtém revisão prioritária da FDA para Trodelvy no câncer de mama HR+/HER2-
Fonte: FirstWord Pharma (Texto original, publicado em inglês) Gilead nabs FDA priority review for Trodelvy in HR+/HER2- breast cancer Gilead Sciences on Tuesday announced that Trodelvy (sacituzumab govitecan-hziy) has been granted a priority review by the FDA for another breast cancer indication. The designation is for a supplemental filing requesting that the Trop-2-directed antibody be